An anti-miR17 oligonucleotide is in Phase 1b in ADPKD patients to de-repress multiple miR-17 mRNA targets including Pkd1 and Pkd2 (Lakhia et al., 2022; https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-first-patient-dosed-in-phase-1b-multiple-ascending-dose-mad-clinical-trial-of-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-301665896.html). The gene discussed is PKD1; the disease is autosomal dominant polycystic kidney disease.